Changes in biologic features between primary and recurrent or relapsed breast cancers
|
|
- Ernest Mills
- 8 years ago
- Views:
Transcription
1 Changes in biologic features between primary and recurrent or relapsed breast cancers S. Al-Awadi, S. Thuruthel, K. Yamini, P. Muraligopal, I. Maarouf, A. Atta Department of Medical Oncology, Kuwait Cancer Control Centre, Kuwait Abstract Objective: Changes in ER, PR and Her2 receptor status between primary and metastatic cancer tissue have been suggested in breast cancer. The frequencies of these changes are still not fully understood. The purpose of this study was to evaluate these changes in breast cancer population of Kuwait. Subjects and Method: Changes in the biological features between primary and recurrent disease in 70 patients who presented between 2009 and 2012 was studied. Statistical comparisons between groups was done using chi square test while Kaplan Meier method was used to perform analysis of survival after relapse. All analysis was carried out using the IBM-SPSS statistical software. Results: There was a decrease in ER and PR positivity from 61.4% to 58.6% and 61.4% to 44.3% respectively. The overall change in ER and PR status was 28.5% and 25.7% respectively. There was an increase in the Her2 positivity as the tumor relapsed and overall changes were seen in 5.7% of cases. Conclusion: Patients with breast cancer experience change in biological markers through the course of their disease. The changes are more with hormone receptors compared to Her2. Re-biopsy should be considered at relapse if feasible. Keywords: breast cancer, hormone receptors, Her2 neu, receptors, biological features, changes Introduction Determination of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2) has become an integral part of the treatment paradigm of breast cancer (1). These markers have helped us in classifying breast cancer into various subtypes as well as in prognosticating and determining therapeutic options (2). In the adjuvant setting, it is important in the determination for the need of chemotherapy, hormonal and Her2 targeted therapy with Trastuzumab. In metastatic disease, these biological markers along with disease free survival and sites of recurrence help us choose the various treatment options (3, 4). Corresponding Author: Dr. Sanjay Thuruthel, Department of Medical Oncology, Kuwait Cancer Control Centre, P.O. Box 42262, Shuwaikh 70653, Kuwait. Tel. No , sthuruthel@hotmail.com 19 It has been shown that these markers can vary in initial resected primary tumor as well as in metastatic tumor (5-7). Although treatment of recurrent disease is based on ER, PR and Her2neu status, re-biopsy of lesions has not become a required standard of care. NCCN recommends biopsy of lesions whenever feasible (4). The biological change is mainly in the hormonal receptors while few changes are seen in the Her2neu receptors. A few studies have been published showing changes even in the Her2neu positivity. The discordances in the various studies are in the range of 0-34 % (8-11). It has been hypothesized that differences in primary tumor and metastatic tumor could be a result of genetic drift during progression or intra tumoral heterogeneity wherein the clone with more aggressive phenotype starts micro metastatic process from the beginning (12,13). It also has been proposed that treatment might also
2 Changes in biology of breast cancer on relapse, Sanjay Thuruthel, et. al. interfere with the results by selecting resistant clones. But there is controversy regarding whether the physician will change the treatment depending on the results and whether it will affect the overall prognosis of patients (14, 15). The aim of this study was to collect data regarding change in biological features between primary and recurrent breast cancer from the same patients of the Kuwait population. Patients and methods Kuwait Cancer Control Centre [KCCC] is the only comprehensive oncology centre catering to the population of Kuwait. All breast cancer patients presenting with relapse or recurrent disease and attending the centre between June 2009 and June 2012 were counseled for rebiopsy from the recurrent/metastatic site. ER and PR status were assessed by IHC studies with a threshold of 10% or more to be classified as positive. Her 2 was initially assessed by IHC and a score 3+ was taken as positive. Patients with an equivocal IHC score of 2+ had FISH done with a threshold her2neu/cep17 ratio 2 taken as positive or amplified. These results were then compared with the retrospective data available in the registry of the ER, PR and Her2 status of the primary tumor for these patients. The patients were classified as: Hormone Receptor (HR) positive and Her2 negative tumors were classified as luminal A type, HR and Her2 positive tumors as luminal B type, HR negative and Her2 positive as Her2 type, and HR and Her2 negative as Triple negative (TN) type. Statistical comparison between groups was done using chi square test while Kaplan-Meier method was used to perform analysis of survival after relapse according to biological marker change. The log-rank statistic was used for univariate comparisons of survival end points. For univariate and multivariate comparisons, a logistic regression model was used. All analyses were carried out using the IBM-SPSS statistical software. The median time period of observation after recurrence was 13 months. The baseline characteristics of all the patients with recurrent breast cancer enrolled in this study is presented in (Table 1). 20 Seventy patients had the pathology verification for both primary and recurrent tumor. The median age was 51years. 85.7% of patients had tumor greater than 2 centimeters while 22.9% had node negative disease. 61.4% had ER and PR positive disease initially while 27.1% were Her2 positive. Table 1: Characteristics of all patients with recurrent breast cancer in this study [n=70]
3 42.9% had disease free interval (DFI) of 2-5 years while 37.1% had > 5 years. The common sites of biopsy were chest wall (34.3%) and liver (14.2%). G. J. O. Issue 15, 2014 in ER, PR and Her2 occurred in patients having DFI greater than 2 years. Changes in subtype of tumor are shown in (Table 5). The discordance rate was maximum for Luminal B subtype. Results The changes in biological marker status between primary and matched recurrent tumors are shown in Table 2-5. The overall change in positivity for ER was 61.4% to 58.6%, for PR it was 61.4% to 44.3%, and for Her2 it was 27.1% to 30% in the recurrent tumor when compared to the primary tumor. Changing from hormone positive to negative was common for both ER and PR. PR showed more patients becoming negative than positive compared to ER. More patients had Her2nue positive tumor at relapse compared to primary tumor. Category changes for each biological marker and correlation with DFI is shown in (Table 4). The biggest change Table 2: Changes in positivity rates of biological markers between primary and relapsed/recurrent tumor Table 3: Changes in biological marker status between primary breast tumor and relapsed/recurrent tumor Table 4: Changes in biological marker status between primary breast tumor and recurrent tumor based on DFI p value = NS for all parameters Table 5: Changes in breast cancer subtype between primary breast tumors and matched recurrent lesions. p value = <
4 Changes in biology of breast cancer on relapse, Sanjay Thuruthel, et. al. Discussion Discordances in the biological markers between primary and recurrent breast cancer has been documented by several studies. Most published data are from the western world. In our study we present a data on 70 patients from Kuwait. Although our centre caters to the whole population of Kuwait and is the only centre offering oncology services, our study limitation was the difficulty in getting consent for a re-biopsy from breast cancer patients. Data on a large cohort of patients over a period of 10 years was recently described from Stockholm Health care region by Lindstrom et al and also presented at ASCO 2010 showing the instability of ER, PR and Her2 (16). Nishimura et. al. have also published a recent report from Japan on the changing biological markers during relapse (17). The changes in hormone receptors are more frequent than the Her2 changes. In our study, there was a decrease in ER and PR positivity from 61.4% to 58.6% and 61.4% to 44.3% respectively. The overall change in ER and PR status was 28.5% and 25.7% respectively. In the Stockholm study, one in 3 patients experienced an alteration of hormone receptor status at relapse. In the study of Nishimura et. al. there was a decrease in ER positivity from 63.5% to 57.7% and PR from 56.7% to 43.3%. Of note is a larger alteration in PR positivity status at relapse when compared to ER. These results correlate with many study results. Some studies using multivariate analysis have hypothesized that PR positivity changes may be the first change occurring at relapse may indicate poor overall survival. Her2 changes based on various studies have varied values from 0-35%. In our study, there was an increase in the Her2 positivity as the tumor relapsed and overall changes were seen in 5.7% of cases. The largest report on Her2 changes showed discordance in 33.2% with 23.6% changing from positive to negative and 9.6% changing from negative to positive (18). Most changes in the biological markers were seen in patients with a disease free interval (DFI) of > 2 years and the maximum changes were seen Fig. 1 : Survival analysis according to biological marker change. [ p value=0.72] in HR in the patients who relapsed after 5 years, however statistically not significant. Of note is that most patients whose ER changed positive to negative were on hormonal treatment. A study by Guarnaeri et. al. have shown the same results with virtually all of their patients who turned HR negative with relapse having received hormonal therapy and they have hypothesized that this might be due to acquired hormonal resistance (19). An interesting analysis done by Nishimura et. al. is the change in breast cancer subtypes. The discordance rates for Luminal A and B were high at 28.8% and 33.3% respectively while it was low for triple negative and Her2 subtypes. Our study also shows the same where the highest discordance was seen in the Luminal B subtype. The implication on prognosis due to these changes has been studied by some reports. In the study by Lindstrom et. al., patients with ER status that changed from positive to negative had a statistically significant increased hazard ratio for death. However, in our study there was no change in survival with biological marker difference or pathological type change, probably because of short follow-up and less number of events. (Figure 1) 22
5 G. J. O. Issue 15, 2014 There are several limitations of this study. This is a retrospective study and therefore the analysis carries the pitfalls inherent to most retrospective reviews. This was a chart review with the receptor status being typically taken from the pathology report. Some patients have their primary tumor and metastatic tumor tested at different pathology laboratories. There was no central pathology review. This analysis is therefore subject to inter laboratory variations. Secondly, for both hormone receptor and her2 receptor analysis there were often different assay methods used in the primary and metastatic specimens and these could have confounded the results. Despite these limitations, this study with a small number of patients shows that significant receptor discordance occurs between primary and metastatic tumor in breast cancer. Conclusion Patients with breast cancer experience unstable biological markers through the course of their natural history. The changes are more with HR compared to Her2. These changes in biological characteristics may influence treatment decisions taken at relapse and rebiopsy should be considered whenever feasible. References 1. Hortobagyi GN : Treatment of breast cancer. N Engl J Med : Adedayo A, Onitilo, Jessica M, Rober T, Bickol NM: Breast Cancer Subtypes Based on ER/PR and Her2 Expression, Comparison of Clinicopathologic Features and Survival. Clinical Medicine & Research 2009; Volume 7, Number 1/2: Goldhirsch A,Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel members: Thresholds for therapies, highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer Ann Oncol 2009; 20(8): NCCN Clinical Practice Guidelines in Oncology. Breast Cancer; Version 2; Broom RJ, Tang P, Simmons C et al: Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2 status with time: Discordance rates between primary and metastatic breast pathology samples. Anti cancer research 2009; 29(5): Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal Metastases. Ann Onco 2010; 21: Holdaway IM, Bowditch JV: Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ, Larsimont D: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y: Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2011; 28(1): Zidan J, Dashkovsky I, Stayerman C Basher W, Cozocov C, Hadary A: Comparison of HER-2 over expression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: Gong Y, Booser DJ, Sneige N: Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: Edgerton SM, Moore D 2nd, Merkel D et al: erbb- 2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003; 11: Pertschuk LP, Axiotis CA, Feldman JG Constantine A, Joseph GF, Yong DK, Sebastian J, Karavattayhayyil, Lorraine B: Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 1999; 5: Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases. Ann Oncol 2009; 20(9): Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20(12):
6 Changes in biology of breast cancer on relapse, Sanjay Thuruthel, et. al. 16. Lindstrom LS, Karlsson E, Wilking UA, Johansson U, Hartman J et al: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N: Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World Journal of Surgical Oncology 2011; 9: Lower EE, Glass E, Blau R Harman S: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; Jan; 113(2): Guarnaeri V, Giovannelli S, Ficcara G, Bettelli S, Maiorana A, Piacentini F, Barbeiri E, Dieci MV, DAmicoR, Jovic G, Conte P: Comparison of HER- 2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management. The Oncologist 2008; 13:
Receptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?
Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000
More informationDescription of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015
Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationImpact of radiation therapy on survival in patients with triple negative breast cancer
548 Impact of radiation therapy on survival in patients with triple negative breast cancer LAUREN T. STEWARD 1, FENG GAO 2, MARIE A. TAYLOR 3 and JULIE A. MARGENTHALER 1 1 Department of Surgery; 2 Division
More informationEffect of Chemotherapy for Luminal A Breast Cancer
Yonago Acta medica 2013;56:51 56 Original Article Effect of Chemotherapy for Luminal A Breast Cancer Naotaka Uchida,* Takako Suda and Kiyosuke Ishiguro *Clinic of Surgery, Tottori Prefectural Kosei Hospital,
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationPrognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a
More informationPositività per HER-2 nei carcinomi subcentimetrici
Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationAIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes
More informationSECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationComparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
167 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(2): 167-173. doi: 10.7150/jca.10944 Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple
More informationABSTRACT. KEYWORDS Choroidal metastasis; breast cancer; ultrasound analysis; radiotherapy; asymptomatic lesion. zzzzzz
SYMPTOMATIC BILATERAL CHOROIDAL METASTASIS FROM BREAST CANCER AS FIRST CLINICAL SIGN OF ADVANCED METASTATIC TUMOR DISEASE 31 YEARS AFTER DIAGNOSIS KESTELYN PA*, LIBBRECHT L**, DUPREZ F***, COCQUYT V****,
More informationPrognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based
More informationHow To Use A Breast Cancer Test To Help You Choose Chemotherapy
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationAccess to hormone receptor testing and other basic diagnostic pathology services in Colombia
Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Dr Fernando Perry Clínica de seno y tejidos blandos Instituto Nacional de Cancerología de Colombia Breast cancer
More informationBioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy
BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy Soonmyung Paik 1 ; Gyungyub Gong 2 ; Yap Yoon Sim 3 ; Tae- You Kim
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationGuideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationBreast Cancer - Do You Know the Race of Her2?
DOI 10.1186/s40064-015-1538-x RESEARCH Open Access Her2 positivity and race predict higher mastectomy rates: a SEER database analysis Theresa L. Schwartz 1, Jula Veerapong 1 and Leslie Hinyard 2* Abstract
More informationLocal Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125)
Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36125 Original ICD-9 LCD
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationHER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays
O R I G I N A L A R T I C L E HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays TK Yau H Sze Inda S Soong F Hioe
More informationPrognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy
Original Study Prognostic Factors for Triple-Negative Breast Cancer Patients Receiving Preoperative Systemic Chemotherapy Sota Asaga, Takayuki Kinoshita, Takashi Hojo, Junko Suzuki, Kenjiro Jimbo, Hitoshi
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationProportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationMEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationDoes Resection of an Intact Breast Primary Improve Survival in Metastatic Breast Cancer?
rvival in Metastatic Breast Cancer? Review Article [1] July 01, 2007 By Seema A. Khan, MD [2] The recommended primary treatment approach for women with metastatic breast cancer and an intact primary tumor
More informationName of Policy: Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers
Name of Policy: Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers Policy #: 487 Latest Review Date: January 2016 Category: Laboratory Policy Grade: B Background/Definitions:
More informationPATHOLOGY. HercepTestTM. Product Information
PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationThe Value of Patient Advocacy in Laboratory Research--Making an Impact on Metastatic Breast Cancer Through the Rapid Autopsy Program
The Value of Patient Advocacy in Laboratory Research--Making an Impact on Metastatic Breast Cancer Through the Rapid Autopsy Program Lillie Shockney, RN., BS., MAS Administrative Director, Johns Hopkins
More informationHER2/neu (erbb2) Analysis on FNA Smears and Core Biopsies of Primary or Metastatic Breast Cancer. Ann Thor M.D.
PSC/USCAP 2008 Applications of Molecular Analysis to Small Biopsy and Cytology Specimens for Diagnosis and Targeted Therapy HER2/neu (erbb2) Analysis on FNA Smears and Core Biopsies of Primary or Metastatic
More informationOctober is Breast Cancer Awareness Month!
October is Breast Cancer Awareness Month! A STUDY OF CHARACTERISTICS AND MANAGEMENT OF BREAST CANCER IN TAIWAN Eric Kam-Chuan Lau, OMS II a, Jim Yu, OMSII a, Christabel Moy, OMSII a, Jian Ming Chen, MD
More informationBreakthrough Treatment Options for Breast Cancer
Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationYour Guide to the Breast Cancer Pathology Report
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
More informationBREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationQuantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Quantitative Assay for Measurement of HER2 Total Protein Expression
More informationTriple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes
DOI 10.1007/s11060-011-0616-3 CLINICAL STUDY PATIENT STUDY Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes Anna Niwińska Wojciech
More informationIJC International Journal of Cancer
IJC International Journal of Cancer PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy Karin Beelen 1,2, Laurien D.C. Hoefnagel 3, Mark
More informationCorrelation of Breast Cancer Subtypes Based on ER, PR and HER2 Expression with Axillary Lymph Node Status
Cancer and Oncology Research 2(4): 51-57, 2014 DOI: 10.13189/cor.2014.020402 http://www.hrpub.org Correlation of Breast Cancer Subtypes Based on ER, PR and HER2 Expression with Axillary Lymph Node Status
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationPost-PET Restaging Cancer Form National Oncologic PET Registry
Post-PET Restaging Cancer Form National Oncologic PET Registry Facility ID #: Registry Case Number: Patient Name: Your patient had a PET scan on: mm/dd/yyyy. The PET scan was done for restaging of (cancer
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationMeasures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
Breast Cancer Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario MARTA BONOTTO, a LORENZO GERRATANA, a,c ELENA POLETTO, a PAMELA DRIOL, d MANUELA GIANGRECO, c STEFANIA
More informationer, pr, HeR2, Ki-67 and ck5 in early and Late Relapsing Breast cancer Reduced ck5 expression in Metastases
Breast Cancer: Basic and Clinical Research ORiginAL ReSeARCh Open Access Full open access to this and thousands of other papers at http://www.la-press.com. er, pr, HeR2, Ki-67 and ck5 in early and Late
More informationSAMO FoROMe Post-ESMO 2013 Breast Cancer
SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationTherapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes
ONCOLOGY LETTERS 12: 663-669, 2016 Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes IPPEI FUKADA 1, KAZUHIRO ARAKI 1, KOKORO KOBAYASHI 1, TAKAYUKI KOBAYASHI
More informationLaboratory Testing for Her2 Status in Breast Cancer
Laboratory Testing for Her2 Status in Breast Cancer Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology May 28, 2015 Overview Clinical relevance of Her2 status for treatment of breast
More informationMetastatic Breast Cancer: The Art and Science of Systemic Therapy. Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba
Metastatic Breast Cancer: The Art and Science of Systemic Therapy Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba Presenter Disclosure Faculty: Dr. Vallerie Gordon Relationships with commercial
More informationBreast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer.
Breast Cancer What Does the Pathology Report Say Normal Cells The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Non-Invasive
More informationAdjuvant Therapy with Trastuzumab
Adjuvant Therapy with Trastuzumab Hiroji Iwata, M.D. Department of Breast Oncology, Aichi Cancer Center Hospital Although this presentation includes information regarding pharmaceuticals (including products
More informationNancy E. Davidson, MD Johns Hopkins University. Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationNew Treatment Advances for Breast Cancer
New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationNon-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
More informationLocal control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More informationPROGNOSIS AND PREDICTIVE FACTORS IN HUMAN BREAST CANCER DURING TUMOR PROGRESSION. Eva Karlsson
From THE DEPARTMENT OF ONCOLOGY-PATHOLOGY Karolinska Institutet, Stockholm, Sweden PROGNOSIS AND PREDICTIVE FACTORS IN HUMAN BREAST CANCER DURING TUMOR PROGRESSION Eva Karlsson Stockholm 2014 . Published
More informationInflammatory Breast Cancer: A Unique Pathologic Entity?
Inflammatory Breast Cancer: A Unique Pathologic Entity? Sandra M. Swain, M.D. Director, Washington Cancer Institute Washington Hospital Center Washington DC Outline Overview Therapy High dose chemotherapy
More informationMale Breast Cancer in Singapore: 15 Years of Experience at a Single Tertiary Institution
247 Original Article Male Breast Cancer in Singapore: 15 Years of Experience at a Single Tertiary Institution Jin Yao Teo, 1 MBBS, MRCS, Puay Hoon Tan, 2 MD, FRCPA,Wei Sean Yong, 1 MBBS, FRCS Abstract
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationAdjuvant treatment of breast cancer patients with trastuzumab
doi:10.2478/v10019-007-0020-y review Adjuvant treatment of breast cancer patients with trastuzumab Erika Matos, Tanja Čufer Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia
More informationSurvival Analysis of Male Breast Carcinoma
Survival Analysis of Male Breast Carcinoma Mariana Martins Epifânio Frazão Aparício Under supervision of Giovani Loiola da Silva and António Evaristo Pinto Instituto Superior Técnico, Lisbon, Portugal
More informationHER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges
Technical Articles HER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges Christa L. Whitney-Miller, MD David G. Hicks, MD Department of Pathology
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationwww.downstatesurgery.org
Male Breast Cancer Rabih Nemr MD Kings County Hospital August 2008 ACGME Core Competencies 1 Patient t Care Medical Knowledge 2 g 3 4 Practice Based Learning/Improvement Interpersonal Communication Skills
More informationBreast. Patient information. cancer clinical pathway
Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationCirculating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers
Review For reprint orders, please contact reprints@future-drugs.com Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers Walter P Carney CONTENTS Monitoring of HER2/neu oncoproteins
More informationMeasurement of HER2. Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center
Measurement of HER2 Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center Trastuzumab Metastatic Adjuvant Lapatinib Metastatic Trials Why Test
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
More information